2025 年 4 月 27 日 贤丰控股股份有限公司 董事会 贤丰控股股份有限公司 关于独立董事 2024 年度独立性评估的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，贤丰控股股份有限公司（以下简称公司）董事会就公 司现任独立董事肖世练、邓延昌、梁融在 2024 年度的独立性情况进行评估并出 具如下专项意见： 经核查现任独立董事肖世练、邓延昌、梁融的任职经历以及签署的相关自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东 公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》中对独立董事独立性的相关要求。 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （梁融） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"或"贤 丰控股"）的独立董事，根据《上市公司独立董事管理办法》及《独立董事工作 制度》的相关规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人梁融，律师执业经验逾10年，曾任北京市盈科（深圳）律师事务所合伙 人律师、万商天勤（深圳）律师事务所合伙人律师，现任广东知恒律师事务所股 权高级合伙人，兼任深圳市长盈精密技术股份有限公司（300115.SZ）独立董事、 深圳市一搏科技股份有限公司（301366.SZ）独立董事，2020年5月21日起任公司 独立董事。 本人不在贤丰控股担任除独立董事外的其他职务，经自查，与贤丰控股及其 主要股东不存在直接或间接利害关系，或者其他可能影响本人独立性的关系，满 足有关规定中对于出任贤丰控股独立董事所应具备的独立性要求。 二、年度履职概况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席2次，以线上会议方 式出席2次；公司召开董事会会议13次，本人以现场方式出席4次，以线上会议方 式出席9次；均无委托出 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （肖世练） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"或 "贤丰控股"）的独立董事，根据《上市公司独立董事管理办法》及《独立董 事工作制度》等相关规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人肖世练，博士研究生学历，中国注册会计师，国际注册内部审计师。 曾供职于广州海关、普华永道会计师事务所、安永会计师事务所、广州农村商 业银行股份有限公司、粤港澳大湾区产融投资有限公司，现任职于广州健博企 业服务有限公司，兼任蜂助手股份有限公司（301382.SZ）、深圳市佳士科技股 份有限公司（300193.SZ）、深圳市新涛新材料股份有限公司、深圳市皓吉达电 子科技股份有限公司的独立董事，2023年10月9日起任公司独立董事。 本人不在贤丰控股担任除独立董事外的其他职务，与贤丰控股及其主要股 东不存在直接或间接利害关系，或者其他可能影响本人独立性的关系，满足有 关规定中对于出任贤丰控股独立董事所应具备的独立性要求。 二、年度履职情况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席1次，以线上 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （邓延昌） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"、"贤 丰控股"）的独立董事，根据《上市公司独立董事管理办法》以及《独立董事工 作制度》的规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人邓延昌，教授级高级工程师，曾任辽宁有色地质勘查总院院长、国家危 机矿山接替资源勘查监审专家、银泰黄金股份有限公司（000975.SZ）独立董事。 2020年1月23日起任公司独立董事，无其他兼职情况。 本人不在贤丰控股担任其他职务，与贤丰控股及其主要股东不存在直接或间 接利害关系，或者其他可能影响本人独立性的关系，满足有关规定中对于出任贤 丰控股独立董事所应具备的独立性要求。 二、年度履职概况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席3次，以线上会议方 式出席1次；公司召开董事会会议13次，本人以现场方式出席5次，以线上会议方 式出席8次；均无委托出席和缺席情形，本人对提交董事会审议的各项议案均表 示同意，无反对或弃权情形。 （五）与中小投资者沟通交流情况 （二）参与董事会专门委员会、独 ...

Financial Performance - The company's operating revenue for 2024 was ¥440,478,600.49, representing a 400.31% increase compared to ¥88,040,600.80 in 2023[20]. - The net profit attributable to shareholders for 2024 was -¥113,006,166.29, a slight improvement of 5.92% from -¥120,115,833.29 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥479,582,657.09, a significant decline of 818.32% compared to -¥52,224,007.16 in 2023[20]. - Total assets at the end of 2024 reached ¥1,470,823,932.83, an increase of 23.33% from ¥1,192,593,505.11 at the end of 2023[20]. - The company's net assets attributable to shareholders decreased by 20.44% to ¥820,299,187.95 at the end of 2024 from ¥1,031,077,872.65 at the end of 2023[20]. - Non-recurring gains for 2024 amounted to ¥18,295,621.80, compared to ¥12,380,814.32 in 2023, primarily from asset disposals and government subsidies[25][26]. - The company's basic earnings per share for 2024 was -¥0.1045, a slight improvement of 1.32% from -¥0.1059 in 2023[20]. - The total amount of accounts receivable confirmed during the reporting period was ¥6,737.57 million[52]. - The company's total operating costs reached ¥405,224,302.75, a significant increase of 688.43% compared to the previous year[55]. - The total distributable profit for the reporting period was -419,349,894.07 CNY, indicating a loss[130]. Business Operations - The main business operations include veterinary vaccines, copper-clad laminates, and animal nutrition (feed) as of the report date[18]. - The company has strategically exited the fine enameled wire business as of the end of Q3 2022, focusing on its new business segments[18]. - The animal nutrition business has seen monthly sales growth due to increased market demand, despite being in its early development stage with only 2 months of operational experience[34]. - The company has established a comprehensive procurement management system to reduce costs while ensuring stable quality, adapting to market changes[33]. - The company is focusing on enhancing product quality, optimizing sales channels, and improving production capacity to better its profitability[36]. - The company has implemented a strategic transformation to improve operational conditions and expand its business scope, aiming to eliminate delisting risk warnings[43]. - The company has upgraded its production facilities to meet the latest GMP standards, ensuring the safety, effectiveness, and quality stability of its vaccines[39]. - The company aims to position itself as a "vaccine process expert and disease solution expert," focusing on high-quality vaccine production and comprehensive technical services for livestock farms[40]. Market Conditions - The company reported a significant decline in the pig farming industry, with a 3.31% decrease in the national pig slaughter volume to 703 million heads in 2024[28]. - The average price of pigs showed signs of recovery starting in Q2 2024, but this did not translate to improved conditions for upstream animal health companies[28]. - The company faced intense competition in the animal health sector, with price wars becoming the norm due to prolonged payment cycles and low bidding standards[28]. - The pig vaccine business has faced increased competition, leading to a decline in product gross margins and longer accounts receivable periods[33]. - The feed industry is evolving towards green and intelligent production in response to environmental policies and customized demands[29]. Research and Development - The company has established a comprehensive innovation system through collaborations with top research institutions, resulting in 9 new veterinary drug registration certificates and 33 invention patents[37]. - A new live vaccine for pseudorabies (JS-A1 strain) developed in collaboration with the Chinese Academy of Agricultural Sciences received a new veterinary drug certificate in November 2024, marking it as the first of its kind in China[38]. - The company has a total of 31 vaccine products registered, including 15 for pigs and 16 for poultry, and continues to enhance its product offerings to strengthen market competitiveness[39]. - R&D investment increased by 28.89% to ¥15,564,041.87 in 2024, while the proportion of R&D investment to operating revenue decreased to 3.53% from 13.72%[63]. - The number of R&D personnel rose by 29.55% to 57 in 2024, with a significant increase in master's degree holders by 41.18%[63]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations and decision-making processes[97]. - The board of directors consists of 7 members, including 3 independent directors, meeting regulatory requirements for governance[98]. - The company has implemented a strategic plan to enhance market competitiveness and is committed to ongoing innovation in response to industry trends and customer needs[90]. - The company has established a comprehensive investor relations management system to enhance communication and ensure investors' rights are protected[99]. - The company has implemented a public opinion response management system to effectively handle various public sentiments impacting stock prices and business reputation[99]. Environmental Compliance - The company has complied with all relevant environmental protection laws and regulations during its operations[141]. - The total investment in environmental protection measures for 2024 by Shiji Biological amounted to CNY 268,360, including wastewater treatment agents, environmental taxes, hazardous waste disposal, and equipment maintenance[150]. - The companies are actively complying with local environmental regulations and have established measures to manage and monitor their emissions[145]. - Shiji Biological successfully executed its environmental self-monitoring plan during the reporting period without any exceedances[147]. Shareholder Relations - The company reported a profit distribution plan of 0 cash dividends and 0 bonus shares per 10 shares for all shareholders[5]. - The company did not propose any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[132]. - The company plans to maintain its share repurchase strategy in 2024 but will not distribute cash dividends or issue bonus shares[132]. - The participation rate for the 2024 first extraordinary shareholders' meeting was 40.17%[102]. - The company completed the repurchase of 101,720,721 shares, accounting for 8.96% of the total share capital, which is treated as a cash dividend[128]. Risks and Challenges - The company has faced a decline in its veterinary vaccine business for two consecutive years, with sales at a low level, indicating high market competition risks[89]. - The company is addressing raw material price volatility risks, which could significantly impact costs and profits, by closely monitoring market trends and exploring strategic supplier relationships[92]. - The company has a high customer concentration in its feed business, which poses risks if customer relationships deteriorate; it plans to actively develop new markets to mitigate this risk[91]. - The company emphasizes the importance of managing accounts receivable to prevent bad debt risks as its business scales up, despite currently having a low bad debt rate[93]. Audit and Compliance - The company received a standard unqualified audit report for the 2024 fiscal year, with audited revenue exceeding 300 million yuan[188]. - The 2023 audit report highlighted concerns regarding the controlling shareholder's bankruptcy proceedings, which have since been addressed, ensuring no significant impact on the company's operations[187]. - The company identified and corrected significant internal control deficiencies related to revenue recognition and inflated income from subsidiary Chengdu Shiji Bio-Pharmaceutical Co., Ltd., with corrections made prior to the annual report[189][190]. - The company has implemented measures to strengthen internal controls, including revising organizational structures and enhancing management oversight to prevent future issues[191].

贤丰控股股份有限公司 2025 年第一季度报告 证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-035 贤丰控股股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 | | | 单位：元 | | --- | --- | --- | | 项目 | 本报告期金额 | 说明 | | 非流动性资产处置损益（包括已计提资产减值准备的冲销部分） | 18,488,785.48 | 主要系出售珠海厂房土地部分 完成过户及成都史纪技术合同 | | | | 转让所致 | 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告 ...

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-022 贤丰控股股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1. 根据《深圳证券交易所股票上市规则》(2024 年修订）第 9.3.6 条的规 定，公司应当在股票交易被实施退市风险警示当年会计年度结束后一个月内，披 露股票可能被终止上市的风险提示公告，在首次风险提示公告披露后至年度报告 披露前，每十个交易日披露一次风险提示公告。本次公告为公司第六次风险提示 公告，敬请广大投资者理性投资，注意投资风险。 2. 公司于 2024 年 4 月 26 日披露了《关于公司股票交易实施退市风险警示 和其他风险警示暨停复牌公告》（公告编号：2024-036），因公司 2023 年度归 属于上市公司股东的净利润为负值且扣除后营业收入低于 1 亿元，根据《深圳证 券交易所股票上市规则》（2023 年 8 月修订）相关规定，公司股票于 2024 年 4 月 29 日起被实施退市风险警示。若公司 2024 年度出现《深圳证券交易所股票上 市规则 ...

一、2023 年度审计报告非标审计意见涉及事项影响的消除情况 证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-021 贤丰控股股份有限公司 关于 2024 年年度报告编制及审计进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（以下简称"贤丰控股"）根据《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》的 相关规定，公司应当分别在年度报告预约披露日前二十个交易日和十个交易日， 披露年度报告编制及最新审计进展情况，相关情况如下： 1、关于带强调事项段的无保留意见审计报告所涉及事项 公司 2023 年度财务报告被北京兴华会计师事务所（特殊普通合伙）（以下 简称"兴华所"）出具了带强调事项段的无保留意见审计报告，相关强调事项段 提示投资者关注公司控股股东及其一致行动人存在影响公司控制权的事项、公司 股票存在因触及财务类强制退市条件被实施退市风险警示的情形。 截至本公告披露日，由于公司控股股东及其一致行动人积极寻求保持控制权 稳定的解决方案，其破产清算事项不影响公司正常生产经营 ...

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-020 贤丰控股股份有限公司 关于公司股份被公开拍卖完成过户的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（简称"公司"）控股股东贤丰控股集团有限公司（简 称"贤丰集团"）及其一致行动人广东贤丰控股有限公司（简称"广东贤丰"） 持有的公司 5,400 万股股票在京东拍卖平台上进行公开拍卖，其中：2,900 万股、 2,500 万股已经先后有竞拍结果、被裁定过户，4,500 万股已完成过户，近日公 司通过中国证券登记结算有限责任公司系统获悉，前述 5,400 万股中的 900 万股 已完成过户登记手续，现将有关进展情况公告如下： 一、股份拍卖情况 贤丰集团及其一致行动人广东贤丰持有的公司 5,400 万股股票在京东拍卖 平台上进行公开拍卖，买受人朱兴虎、吴宪彬分别竞得贤丰集团持有的公司股票 1,000 万股、1,000 万股，买受人吴宪彬竞得广东贤丰持有的公司股票 900 万股， 买受人陈新熊、江西鑫余环境科技有限公司分别竞得贤丰集团持有的公司股票 1,389 ...